Does directly observed therapy (DOT) reduce drug resistant tuberculosis?

Patrick K Moonan, Teresa N Quitugua, Janice M Pogoda, Gary Woo, Gerry Drewyer, Behzad Sahbazian, Denise Dunbar, Kenneth C Jost Jr, Charles Wallace, Stephen E Weis, Patrick K Moonan, Teresa N Quitugua, Janice M Pogoda, Gary Woo, Gerry Drewyer, Behzad Sahbazian, Denise Dunbar, Kenneth C Jost Jr, Charles Wallace, Stephen E Weis

Abstract

Background: Directly observed therapy (DOT) is a widely recommended and promoted strategy to manage tuberculosis (TB), however, there is still disagreement about the role of DOT in TB control and the impact it has on reducing the acquisition and transmission of drug resistant TB. This study compares the portion of drug resistant genotype clusters, representing recent transmission, within and between communities implementing programs differing only in their directly observed therapy (DOT) practices.

Methods: Genotype clusters were defined as 2 or more patient members with matching IS6110 restriction fragment length polymorphism (RFLP) and spoligotype patterns from all culture-positive tuberculosis cases diagnosed between January 1, 1995 and December 31, 2001. Logistic regression was used to compute maximum-likelihood estimates of odds ratios (ORs) and 95% confidence intervals (CIs) comparing cluster members with and without drug resistant isolates. In the universal DOT county, all patients received doses under direct observation of health department staff; whereas in selective DOT county, the majority of received patients doses under direct observation of health department staff, while some were able to self-administer doses.

Results: Isolates from 1,706 persons collected during 1,721 episodes of tuberculosis were genotyped. Cluster members from the selective DOT county were more than twice as likely than cluster members from the universal DOT county to have at least one isolate resistant to isoniazid, rifampin, and/or ethambutol (OR = 2.3, 95% CI: 1.7, 3.1). Selective DOT county isolates were nearly 5 times more likely than universal DOT county isolates to belong to clusters with at least 2 resistant isolates having identical resistance patterns (OR = 4.7, 95% CI: 2.9, 7.6).

Conclusions: Universal DOT for tuberculosis is associated with a decrease in the acquisition and transmission of resistant tuberculosis.

Figures

Figure 1
Figure 1
Study population.

References

    1. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med. 1990;112:407–415.
    1. Dutt AK, Moers D, Stead WW. Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin. Community physicians' seven-year experience with mainly outpatients. Am J Med. 1984;77:233–242. doi: 10.1016/0002-9343(84)90697-1.
    1. Horsburgh CR Jr. The global problem of multidrug-resistant tuberculosis: The genie is out of the bottle. JAMA. 2000;283:2575–2576. doi: 10.1001/jama.283.19.2575.
    1. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: Effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med. 1990;112:397–406.
    1. Benator D, Bhattacharya M, Bozeman L. et al.Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: A randomised clinical trial. Lancet. 2002;360:528–534. doi: 10.1016/S0140-6736(02)09742-8.
    1. Centers for Disease Control and Prevention. Outbreak of multi-drug resistant tuberculosis-Texas, California, and Pennsylvania. MMWR. 1990. pp. 369–372.
    1. Dixon W, Stradling P, Wooten I. Outpatient P.A.S. therapy. Lancet. 1957;2:871–872. doi: 10.1016/S0140-6736(57)90006-5.
    1. Davis MS. Predicting non-compliant behavior. J Health Soc Behav. 1967;8:265–271. doi: 10.2307/2948420.
    1. Addington WW. Patient compliance: The most serious remaining problem in the control of tuberculosis in the United States. Chest. 1979;76:741–743.
    1. Fox W. Compliance of patients and physicians: Experience and lessons from tuberculosis-II. British Medical Journal Clinical Research Ed. 1983;287:101–105. doi: 10.1136/bmj.287.6385.101.
    1. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment. JAMA. 1989;261:3273–3277. doi: 10.1001/jama.261.22.3273.
    1. Sumartojo E. When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev Respir Dis. 1993;147:1311–1320.
    1. O'Brien R. In: Tuberculosis: A Comprehensive International Approach. Reichman L, Hershfield E, editor. Vol. 66. New York: Marecel Dekker; 1993. The treatment of tuberculosis; pp. 207–240.
    1. World Health Organization. WHO report on the tuberculosis epidemic 1997. Geneva: World Health Organization; 1997.
    1. What is DOTS?
    1. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus statement of the public health tuberculosis guidelines panel. JAMA. 1998;279:943–948. doi: 10.1001/jama.279.12.943.
    1. Garner P. What makes DOT work? directly observed therapy. Lancet. 1998;352:1326–1327. doi: 10.1016/S0140-6736(05)60739-8.
    1. Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet. 1998;352:1340–1343. doi: 10.1016/S0140-6736(98)04022-7.
    1. Volmink J, Garner P. Directly observed therapy for treating tuberculosis.[update of Cochrane Database Syst Rev. 2001;(4):CD003343; PMID: 11687192] Cochrane Database of Systematic Reviews. 2003. p. 003343.
    1. DeRiemer K, Garcia-Garcia L, Bobadilla-del-Valle M. et al.Does DOTS work in populations with drug-resistant tuberculosis? Lancet. 2005;365:1239–1245. doi: 10.1016/S0140-6736(05)74812-1.
    1. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, Gomez E, Foresman BH. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330:1179–1184. doi: 10.1056/NEJM199404283301702.
    1. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274:945–951. doi: 10.1001/jama.274.12.945.
    1. United States Department of Health and Human Services. Title 45, part 46: Protection of human subjects. General requirements for informed consent. Code of Federal Regulations. 2001.
    1. Annas GJ. Control of tuberculosis--the law and the public's health. N Engl J Med. 1993;328:585–588. doi: 10.1056/NEJM199302253280825.
    1. Burman WJ, Cohn DL, Rietmeijer CA, Judson FN, Sbarbaro JA, Reves RR. Short-term incarceration for the management of noncompliance with tuberculosis treatment. Chest. 1997;112:57–62. doi: 10.1378/chest.112.1.57.
    1. Gasner MR, Maw KL, Feldman GE, Fujiwara PI, Frieden TR. The use of legal action in new york city to ensure treatment of tuberculosis. N Engl J Med. 1999;340:359–366. doi: 10.1056/NEJM199902043400506.
    1. Ellis BA, Crawford JT, Braden CR, McNabb SJ, Moore M, Kammerer S. National Tuberculosis Genotyping and Surveillance Network Work Group. Molecular epidemiology of tuberculosis in a sentinel surveillance population. Emer Inf Dis. 2002;8:1197–1209.
    1. Crawford JT, Braden CR, Schable BA, Onorato IM. National tuberculosis genotyping and surveillance network: Design and methods. Emer Inf Dis. 2002;8:1192–1196.
    1. National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standard. Wayne, PA; 2003. pp. M24–A.
    1. Quitugua TN, Seaworth BJ, Weis SE, Taylor JP, Gillette JS, Rosas II, Jost KC Jr, Magee DM, Cox RA. Transmission of drug-resistant tuberculosis in Texas and Mexico. J Clin Microbiol. 2002;40:2716–2724. doi: 10.1128/JCM.40.8.2716-2724.2002.
    1. Texas Department of Health, Tuberculosis Elimination Division. TB statistics: Cases by county. 2005.
    1. Bishai WR, Graham NM, Harrington S, Pope DS, Hooper N, Astemborski J, Sheely L, Vlahov D, Glass GE, Chaisson RE. Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA. 1998;280:1679–1684. doi: 10.1001/jama.280.19.1679.
    1. Barnes PF. Reducing ongoing transmission of tuberculosis. JAMA. 1998;280:1702–1703. doi: 10.1001/jama.280.19.1702.
    1. Mushtaque A, Chowdhury R. Success with the DOTS strategy. Lancet. 1999;353:1003–1004. doi: 10.1016/S0140-6736(99)02119-4.
    1. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: History of an idea. Lancet. 1995;345:1545–1548. doi: 10.1016/S0140-6736(95)91090-5.
    1. Weis SE. Universal directly observed therapy. A treatment strategy for tuberculosis. Clin Chest Med. 1997;18:155–163. doi: 10.1016/S0272-5231(05)70365-8.
    1. Kochi A, Vareldzis B, Styblo K. Multidrug-resistant tuberculosis and its control. Res Microbiol. 1993;144:104–110. doi: 10.1016/0923-2508(93)90023-U.
    1. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328:527–532. doi: 10.1056/NEJM199302253280802.
    1. Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: Predictors and consequences in New York City. Am J Med. 1997;102:164–170. doi: 10.1016/S0002-9343(96)00402-0.
    1. Geng E, Kreiswirth B, Driver C, Li J, Burzynski J, DellaLatta P, LaPaz A, Schluger NW. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med. 2002;346:1453–1458. doi: 10.1056/NEJMoa012972.
    1. Sahbazian B, Weis SE. Treatment of active tuberculosis: challenges and prospects. Clin Chest Med. 2005;26(2):273–82. doi: 10.1016/j.ccm.2005.02.011.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi